Q1 2026 Earnings Calendar: Key Conference Calls for Hansa Biopharma, RenaissanceRe, and Stella-Jones
As the first quarter of 2026 concludes, investors and analysts are turning their attention to upcoming financial disclosures. Several key players across the biopharmaceutical, insurance, and industrial sectors have scheduled their interim results calls, providing critical insights into their operational performance and strategic pipelines.
Hansa Biopharma to Detail Pipeline and Financials on April 23
Hansa Biopharma (Nasdaq Stockholm: HNSA), a commercial-stage biopharmaceutical company focusing on immunomodulatory therapies, will publish its interim report for the period of January through March 2026 on April 23, 2026.
The company has scheduled a quarterly conference call for the same date at 14:00 CEST / 8:00 AM EDT. The session will be led by a comprehensive management team:
- Renée Aguiar-Lucander, CEO
- Evan Ballantyne, CFO
- Richard Philipson, CMO
- Maria Törnsén, COO and President U.S.
During the call, management is expected to review interim financial results and provide updates on the company’s business and pipeline. This includes their proprietary IgG-cleaving enzyme technology platform, featuring imlifidase for kidney transplantation and HNSA-5487, which is being developed for Guillain-Barré Syndrome (GBS).
RenaissanceRe Sets First Quarter Results Date
RenaissanceRe Holdings Ltd. (NYSE: RNR) has announced it will conduct an investment community conference call on Wednesday, April 29, 2026. The call is scheduled for 11:00 a.m. ET.
The primary objective of the call is to discuss the company’s financial results for the first quarter of 2026 and provide an updated outlook for the remainder of the year.
Stella-Jones Announces Results Call and Annual Meeting
Stella-Jones Inc. (TSX: SJ) will hold a series of important events on Wednesday, May 6, 2026.
The company will first host a conference call to discuss its first quarter results at 8:00 AM Eastern Daylight Time (EDT). Following the results call, the Annual Meeting of Shareholders will take place at 11:00 AM EDT. This will be a hybrid meeting, held both virtually and in-person at 1250 René-Lévesque Blvd. West, suite 3610, in Montréal, Québec.
Q1 2026 Earnings Call Summary Table
| Company | Date | Time (ET/EDT) | Event Type |
|---|---|---|---|
| Hansa Biopharma | April 23, 2026 | 8:00 AM | Interim Results Call |
| RenaissanceRe | April 29, 2026 | 11:00 AM | Financial Results Call |
| Stella-Jones | May 6, 2026 | 8:00 AM | First Quarter Results Call |
| Stella-Jones | May 6, 2026 | 11:00 AM | Annual Meeting of Shareholders |
Key Takeaways for Investors
- Biotech Pipeline Focus: Hansa Biopharma’s call will be pivotal for those tracking IgG-cleaving enzyme therapies and their application in transplantation and autoimmune diseases.
- Insurance Outlook: RenaissanceRe’s call on April 29 will provide the necessary outlook on the company’s financial trajectory for 2026.
- Corporate Governance: Stella-Jones is combining its financial reporting with its Annual Meeting of Shareholders, allowing investors to move directly from Q1 data to corporate governance discussions.
As these companies report their figures, the market will be looking for signals regarding pipeline progression in biotech and overall fiscal health in the industrial and insurance sectors. Investors should monitor official company websites for webcast links and dial-in details as these dates approach.